3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lung Neoplasms
5
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Camurati-Engelmann Syndrome
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts